DOCSLIB.ORG

Fighting the Opioid Crisis a Screening Guide for Abused Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fighting the Opioid Crisis a Screening Guide for Abused Drugs REFERENCE GUIDE Fighting the Opioid Crisis A screening guide for abused drugs Parent Drug / Trade Names / Detection * References Metabolite Street Names time in Urine* Buprenorphine / R Kronstrand, I Nyström, M Andersson, L Gunnarsson S Hägg, M Suboxone®, Subutex® Josefsson, J Ahlner. Urinary Detection Times and Metabolite/Parent Norbuprenorphine 1-7 days Bupe Compound Rates After a Single Dose of Buprenorphine. J Anal Tox, Vol, (metabolite) 32, oct 2008, 586-593 Fentanyl / Fentora® 3-4 days RC Baselt, Disposition of Toxic Drugs and Chemicals in Man, 11th Edition, Biomedical Publications, Seal Beach, CA, 2017 pgs 883-886 [Fentanyl] Norfentanyl (metabolite) China White Up to 72 hours Heroin Metabolite (6-AM) Smack, Hell Dust, Junk, KE Moeller, CK Lee, JC Kissack, Urine Dug Screening: Practical Guide for Up to 2 days (6-Acetylmorphine) White China Clinicians, Mayo Clin Proc, January 2008:83(1):66-67 Hydrocodone / Vicodin®, Hydro 24 hours EJ Cone, R Heltsley, DL Black, JM Mitchell, CP LoDico, RR Flegel. Prescription Opioids. II. Metabolism and Excretion Patterns of Hydrocodone in Urine Following Controlled Single-Dose Administration. J ® Hydromorphone (metabolite) Dilaudid up to 3 days Anal Tox, 2013:37;486-494 3-14 days in a FG Kapp, HH Maurer, V Auwärter, M Winkelmann, M Hermanns-Clausen. Mitragynine (Kratom*) – NEW! Kratom Intrahepatic Cholestatis Following Abuse of Powdered Kratom (Mitragyna chronic user speciosa) J Med Toxicol (2011) 7:227-231 https://www.health.gov.au/internet/publications/publishing.nsf/Content/ Methadone Dolophine® Dollies 1-4 days drugtreat-pubs-meth-toc~drugtreat-pubs-meth-app~drugtreat-pubs-meth- app4 (Accessed June 3, 2019) ® Rapid On-Site Screening of Drugs of Abuse. United Nations International Meperidine Demerol Demmies 1-3 days Drug Control Programme, Scientific and Technical Notes. December 2001 Codeine (Opiate) Dilaudid® Heroin 2-4 days KE Moeller, CK Lee, JC Kissack, Urine Dug Screening: Practical Guide for Morphine (Opiate metabolite) MS-Contin®, Roxanol®, Up to 2 days Clinicians, Mayo Clin Proc, January 2008:83(1):66-67 Junk, Smack Skag EJ Cone, R Heltsley, DL Black, JM Mitchell, CP LoDico, RR Flegel. Oxycodone / Oxymorphone OxyContin®, Opana® Prescription Opioids. I. Metabolism and Excretion Patterns of Oxycodone Up to 2 days (Metabolite) Blue Heaven, Blues in Urine Following controlled Single Dose Administration. J Anal Tox, 2013:37:255-264 Darvon® https://www.health.gov.au/internet/publications/publishing.nsf/Content/ Propoxyphene 1-2 days drugtreat-pubs-meth-toc~drugtreat-pubs-meth-app~drugtreat-pubs-meth- Darvon Cocktail app4 (accessed June 3, 2019) ® RC Baselt, Disposition of Toxic Drugs and Chemicals in Man, 11th Edition, Tapentadol Nucynta , Cha Cha Up to 5 days Biomedical Publications, Seal Beach, CA, 2017 pgs 2022-2023 Tilidine Valoron®, Valtran® Up to 5 days Ibid, pgs 2108-2109 [Tilidine] Ultram®, ConZip® Tramadol Up to 3 days Ibid, pgs 2147-2150 [Tramadol] Chill Pills, Ultras * Kratom is considered an opioid with potential for abuse. The United States Federal Drug Administration (FDA) statement, February 6, 2019. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner- scott-gottlieb-md-agencys-scientific-evidence-presence-opioid-compounds (accessed May 16, 2019) Thermo Fisher Scientific is Helping to Fight the Opioid Crisis by Offering a Broad Range of Thermo Scientific™ DRI™ and CEDIA™ Opioid Tests Thermo Scientific Parent / Metabolites Cross- Assay Part Numbers Opioid Tests Detected Reactivity Cutoffs Buprenorphine 100% 100190 (3x17 mL), 100240 (65 mL), CEDIA Buprenorphine 5 ng/mL Buprenorphine-glucuronide 98% 10015658 (3x17 mL-Indiko™) Buprenorphine 100% Buprenorphine- -D-glucuronide 125% CEDIA Buprenorphine II β 10 ng/mL 10020849 (3x17 mL), 10020850 (65 mL) Norbuprenorphine 76.9% Norbuprenorphine-β-D-glucuronide 100% Fentanyl 100% Acetyl fentanyl 100% Acryl fentanyl 100% 10016006 (3x18 mL), 10016005 (500 mL), USA only DRI Fentanyl* Butyryl fentanyl 200% 2 ng/mL 10016437 (3x18 mL-Indiko), International only Carfentanil 33.3% Furanyl fentanyl 40% & others Hydrocodone‡ 102% DRI Hydrocodone Hydromorphone‡ 122% 300 ng/mL 10018054 (3x18 mL), 10018053 (500 mL) Hydromorphoine-3β-glucuronide 122% 100107 (3x17mL), 100108 (65 mL), CEDIA Heroin Metabolite (6-AM) Heroin metabolite (6-AM) 100% 10 ng/mL 100186 (495 mL), 10015213 (3x17 mL-Indiko) New! CEDIA Mitragynine (Kratom)† Mitragynine 100% 50 ng/mL 10026604 (3x17 mL), 10026612 (65 mL) Methadone 100% 10016403 (3x18 mL), 0596 (100 mL), DRI Methadone 300 ng/mL Methadol 40% 0597 (500 mL) Methadone 100% 100088 (3x17 mL), 100097 (65 mL), CEDIA Methadone 300 ng/mL Methadol 1.5% 1730916 (495 mL), 10016425 (3x17 mL-Indiko) 10018522 (3x18 mL), 100115 (100 mL), DRI Methadone Metabolite Methadone metabolite (EDDP) 100% 1000 ng/mL 100116 (500 mL) 100087 (3x17mL), 100096 (65 mL), CEDIA Methadone Metabolite Methadone metabolite (EDDP) 100% 100 ng/mL 1868217 (495 mL), 10016421 (3x17mL-Indiko) Codeine 200% 300 ng/mL, 0135 (100 mL), 0136 (500 mL), DRI Opiate Morphine 100% 2000 ng/mL 10014601 (3x18 mL-Indiko) Codeine 125% 100089 (3x17 mL), 100098 (65 mL), CEDIA Opiate 300 ng/mL Morphine 100% 1661248 (495 mL), 10016429 (3x17 mL-Indiko) CEDIA Opiate 2K Codeine§ 102% 2000 ng/mL 100099 (65 mL), 1815296 (495 mL) (2000 ng/mL cutoff) Morphine§ 100% Oxycodone‡ 100% 100248 (68 mL), 100249 (500 mL), DRI Oxycodone 100 ng/mL Oxymorphone‡ 103% 10015632 (3x18 mL-Indiko) Propoxyphene 100% DRI Propoxyphene 300 ng/mL 10018510 (3x18 mL-Indiko), 0160 (100 mL), 0161 (500 mL) Norpropoxyphene 60% Propoxyphene 100% 100170 (3x17 mL), 100171 (65 mL), CEDIA Propoxyphene 300 ng/mL Norpropoxyphene 84.8% 1661523 (495 mL) * USA: For Criminal Justice and Forensic Use Only (CJ&F) International: In Vitro Dignostice (IVD) † USA: For Criminal Justice and Forensic Use Only (CJ&F) Not for sale outside the USA. In the United States: ‡ New to SAMHSA Panel 2017 For customer service, call 1-800-232-3342 § Already part of the SAMHSA panel To fax an order, use 1-800-829-8115 To order online: [email protected] Find out more at thermofisher.com/diagnostics Availability of product in each country depends on local regulatory marketing authorization status. © 2019 Thermo Fisher Scientific Inc. All rights reserved. Thermo Scientific, Indiko, DRI, CEDIA, and the Thermo Fisher Scientific logo are the property of Thermo Fisher Scientific and its subsidiaries. Conzip is a trademark of Cipher Pharmaceuticals, Inc. Darvon is a trademark of Eli Lilly and Company. Demerol is a trademark of U.S. Pharmaceuticals Holdings II, LLC. Dilaudid, OxyContin, MS-Contin are trademarks of Purdue Pharma LP. Dolophine is a trademark of West-Ward Pharmaceuticals. Fentora is a trademark of Cephalon, Inc. or its affliates. Nucynta is a trademark of NF Sub, LLC. Opana is a trademark of Endo International plc or one of its affiliates. Roxanol is a trademark of Xanodyne Pharmaceuticals, Inc. Suboxone and Subutex are trademarks of Indivor UK Limited. Ultram is a trademark of Johnson & Johnson. Valoron is a trademark of Warner-Lambert Company. Valtran is a trademark of Pfizer Manufacturing Deutschland GmbH. Vicodin is a trademark of Abbvie Inc. Corporation. FR-MTL-0145-RG-Opioid-Crisis-EN.
Load more

Recommended publications
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • Misuse and Abuse of Opioid Analgesics – the Role of the Internet
    Misuse and Abuse of Opioid Analgesics – the Role of the Internet H. Siemann, J. Schnell, N. Scherbaum LVR Hospital Essen, Clinic for Dependent Behavior and Addiction Medicine University of Duisburg-Essen, Germany Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Opioid Analgesics • Prescription Drugs – Tramadol, Tilidine, Codeine, Loperamide – Easy to prescribe • Schedule III Drugs according to the German Narcotics Act (BtmG) – Morphine, Methadone, Fentanyl, Buprenorphine, Oxycodone – Special conditions to be fulfilled for a valid presciption Holger Siemann ([email protected]) 2 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Prescription Rate Holger Siemann ([email protected]) 3 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Non-Scheduled Opioids • Tramadol – Pain management (post-surgery treatment, injury treatment) • Tilidine + Naloxone (Valoron N®) – Higher analgesic potency – Prevention of parenteral drug abuse by combination with the µ-receptor antagonist Naloxone Holger Siemann ([email protected]) 4 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Aim of the Study • To assess the role of the internet regarding the abuse of prescription opioids – Role as a trading platform – Role as an information system Holger Siemann ([email protected]) 5 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Methods • Analysis of the first 50 websites provided by the leading search engine Google for
    [Show full text]
  • Narcotic Drugs Stupefiants Estupefacientes
    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
    [Show full text]
  • 0 Cover Part Two\374
    PART TWO DEUXIÈME PARTIE SEGUNDA PARTE ﺍﳉﺰﺀ ﺍﻟﺜﺎﱐ 第二部分 ЧАСТЬ ВТΟΡАЯ - (...), [...] - (-)-3-hidroxi-N- (-)-(2R)-N-méthyl-1- fenacilmorfinán → Levophenacyl-morphan phénylpropan-2-amine → Levometamfetamine (-)-3-hidroxi-N- (-)-(3S,6R)-6- metilmorfinán → Levorphanol (dimethylamino)-4,4- (-)-3-hydroksymorfinan → Norlevorphanol diphenyl-3-heptanol → Betamethadol (-)-3-hydroksy-N- (-)-(3S,6R)-6- fenacylmorfinan → Levophenacyl-morphan (dimethylamino)-4,4- (-)-3-hydroksy-N- diphenyl-3-heptanol metylmorfinan → Levorphanol acetate (ester) → Betacetylmethadol (-)-3-hydroxymorphinan → Norlevorphanol (-)-(5R)-4,5-epoxy-3- (-)-3-hydroxy-N- methoxy-9α-methyl methylmorphinan → Levorphanol → Thebacon morphin-6-en-6-yl acetate (-)-3-hydroxynormorphinan → Norlevorphanol (-)-(5R,6S)-3-benzyloxy-4,5- (-)-3-hydroxy-N- epoxy-9a-methylmorphin- phenacylmorphinan → Levophenacyl-morphan 7-en-6-yl myristate → Myrophine (-)-3-hydroxytropane-2- (-)-(5R,6S)-4,5-epoxy carboxylat → Ecgonine morphin-7-en-3,6-diol → Normorphine (-)-3-idrossi-N- (-)-(5R,6S,14S)-4,5-epoxy- metilmorfinano → Levorphanol 14-hydroxy-3-methoxy- (-)-3-methoxy-N- 9a-methylmorphinan-6- methylmorphinan → Levomethorphan one → Oxycodone (-)-3-metil-2,2-difenil-4- (-)-(R)-4,5-epoxy-3- morfolinbutirilpirrolidina → Levomoramide methoxy-9a-methyl (-)-3-metoksy-N- morphinan-6-one → Hydrocodone metylmorfinan → Levomethorphan (-)-(R)-6-(dimethylamino)- (-)-3-metossi-N-metil- 4,4-diphenyl-3-heptanone → l-methadone morfinano → Levomethorphan (-)-(R)-N,α-dimethyl (-)-3-metoxi-N- phenethylamine → Levometamfetamine
    [Show full text]
  • List of Participants ...8
    WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTI? ENGLISH ONLY REVIEW OF PSYCHOACTIVE SUBSTANCES FOR INTERNATIONAL CONTROL 26-28 SEPTEMBER 1979 CONTENTS Page Introduction ........................................ 2 Scope of the meeting ......................................... 2 Review of drugs for International Control........,........... 3 Sufentanil ................................................. 3 Tilidine..................................................... 3 Dextropropoxyphene .......................................... 4 Phencyclidine ................................................ 4 Phencyclidine analogues ...................................... 5 Mecloqualone ................................................ 5 Selection of further substances requiring control.. .. , . 6 The need for more and better information.. .. .. .. .. 6 List of participants ....................................... 8 List of background documents.. ............................... 10 Annex 1: Summary of the discussion on Investigation of the Stimulant and Reinforcing Properties of Self-Administration of Phenylethylamine Derivatives isolated from Catha.ed. (Khat).. 11-14 e issue of this document does not constitute Ce document ne constitue pas une publication. al publication. It should not be reviewed, II ne doit faire I'objet d'aucun cornpte rendu ou racted or quoted without the agreement of rdsumb ni d'aucune citation sans I'autorisation de e World Health Organization. Authors alone I'Organisation Mondiale de la Sant6. Les opinions responsible for
    [Show full text]
  • Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review
    CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN GUIDELINE FOR THE Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAIN Evidence Review The American Pain Society in Conjunction with The American Academy of Pain Medicine EVIDENCE REVIEW APS-AAPM Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain TABLE OF CONTENTS Page Introduction 1 Purpose of evidence review ...................................................................... 1 Background 1 Previous guidelines ................................................................................... 2 Scope of evidence review 3 Key questions............................................................................................ 3 Populations................................................................................................ 7 Interventions.............................................................................................. 8 Outcomes.................................................................................................. 8 Conflict of interest............................................................................................. 10 Methods 10 Literature search and strategy................................................................... 10 Inclusion and exclusion criteria.................................................................. 11 Data extraction and synthesis ..................................................................
    [Show full text]
  • Narcotic Drugs — Estimated World Requirements for 2018
    English — Comments COMMENTS ON THE REPORTED STATISTICS ON NARCOTIC DRUGS Part two Part Summary The further overall reduction in global stocks and in the production of opium confirm the con- Deuxi tinuing trend towards the eventual elimination of the drug from the international market for è opiate raw material. me partie Poppy straw and concentrate of poppy straw derived from the two main varieties of poppy straw (the morphine-rich and thebaine-rich varieties) decreased slightly in 2016 compared Segunda parte with 2015, and the manufacture of morphine remained stable at 422.1 tons, of which around 87 per cent of global manufacture was converted into other narcotic drugs or into substances not covered by the 1961 Convention. Of the remaining 13 per cent, only 8.6 per cent was directly consumed for palliative purposes. The differences in consumption levels between countries continued to be very significant. In 2016, 80 per cent of the world population consumed only 14 per cent of the total amount of morphine used for the management of pain and suffering. Although that represented an improvement on 2014, when 80 per cent of the world population consumed 9.5 per cent, the disparity in consumption of narcotic drugs for palliative care continues to be a matter of concern. After some fluctuations in the preceding years, global manufacture of thebaine reached the record level of 156 tons in 2016, signalling that the demand for medicines derived from thebaine, after having decreased in the past several years, appears to have resumed, despite restrictions on prescription drugs recently imposed in the main market (the United States of America) in response to their abuse and the high number of overdose deaths they have caused.
    [Show full text]
  • Ensuring Adequate Access for Medical and Scientific Purposes
    INTERNATIONAL NARCOTICS CONTROL BOARD Availability of Internationally Controlled Drugs Controlled Internationally of Availability Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes Indispensable, adequately available and not unduly restricted UNITED NATIONS Reports published by the International Narcotics Control Board in 2015 TheReport of the International Narcotics Control Board for 2015 (E/INCB/2015/1) is supple- mented by the following reports: Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes. Indispensable, adequately available and not unduly restricted (E/INCB/2015/1/Supp.1) Narcotic Drugs: Estimated World Requirements for 2016—Statistics for 2014 (E/INCB/2015/2) Psychotropic Substances: Statistics for 2014—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2015/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2014 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2015/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2013 (January Update)
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Afghanistan Oxycodone 43 000 Codeine 50 000 Oxymorphone 300 Dextropropoxyphene 2 000 000 Pethidine 65 000 Diphenoxylate 20 000 Remifentanil 9 100 Fentanyl 6 Sufentanil 1 Methadone 6 000 Thebaine 45 000 Morphine 4 000 Armenia Pethidine 80 000 Codeine 3 000 Pholcodine 100 000 Fentanyl 21 Albania Methadone 10 000 Codeine 35 000 Morphine 4 500 Fentanyl 40 Thebaine 10 Methadone 9 000 Trimeperidine 650 Morphine 3 000 Aruba* Pethidine 2 500 Alfentanil 3 Pholcodine 1 000 Bezitramide 1 Remifentanil 8 Cocaine 70 Sufentanil 1 Codeine 85 Algeria Dextromoramide 1 Alfentanil 500 Dextropropoxyphene 85 Codeine 1 000 000 Fentanyl 130 Etorphine 1 Hydrocodone 2 Fentanyl 1 000 Methadone 150 Morphine 11 000 Morphine 340 Pethidine 3 000 Opium 450 Pholcodine 2 500 000 Oxycodone 26 Sufentanil 30 Pethidine 404 Andorra Piritramide 20 Fentanyl 80 Remifentanil 19 Methadone 1 000 Ascension Island Morphine 500 Alfentanil 1 Oxycodone 1 500 Fentanyl 1 Pethidine 500 Morphine 2 Remifentanil 4 Pethidine 9 Angola* Australia Alfentanil 2 Alfentanil 400 Codeine 30 000 Cannabis 21 500 Dextromoramide 375 Cocaine 20 000 Dihydrocodeine 375 Codeine 9 800 000 Fentanyl 45 Conc. of poppy straw Morphine 11 000 AOA 4 000 000 Pethidine 13 000 ATA 85 000 000 Sufentanil 2 Dextromoramide 10 Anguilla Dextropropoxyphene 1 925 000 Fentanyl 1 Difenoxin 7 Morphine 20 Dihydrocodeine 285 000 Pethidine 300 Diphenoxylate 80 000 Antigua and Barbuda* Ethylmorphine 10 Cocaine 9 Etorphine 2 Codeine 169 Fentanyl 40 000
    [Show full text]
  • FDA Briefing Document Joint Meeting of the Drug Safety and Risk Management (Dsarm) Advisory Committee and Anesthetic and Analges
    FDA Briefing Document Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) June 11-12, 2019 1 The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the clinical utility and safety concerns associated with the higher range of opioid analgesic dosing (both in terms of higher strength products and higher daily doses) in the outpatient setting, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting. 2 Table of Contents Page Office Director Memorandum 4 Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) Memorandum: Opioids Regulatory Background 9 Division of Epidemiology (DEPI) Review: Prescribing Patterns, Clinical Use, and Risks Associated with Higher Dosage Strength Products and Higher Daily Dosing of Opioid Analgesics 29 3 OFFICE DIRECTOR MEMORANDUM Department of Health and Human Services Public Health Service Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Surveillance and Epidemiology (OSE) Date: May 22, 2019 From: Judy Staffa, Ph.D., R.Ph.
    [Show full text]